Presence and development of diabetic retinopathy in 16 999 patients with type 1 diabetes in the Danish Registry of Diabetic Retinopathy

IF 3 3区医学 Q1 OPHTHALMOLOGY

Acta Ophthalmologica Pub Date : 2024-05-18 DOI:10.1111/aos.16707

Lonny Stokholm, Frederik Nørregaard Pedersen, Nis Andersen, Jens Andresen, Toke Bek, Sebastian Dinesen, Javad Hajari, Steffen Heegaard, Kurt Højlund, Caroline Schmidt Laugesen, Ryo Kawasaki, Sören Möller, Katja Christina Schielke, Yousif Subhi, Anne Suhr Thykjær, Jakob Grauslund

{"title":"Presence and development of diabetic retinopathy in 16 999 patients with type 1 diabetes in the Danish Registry of Diabetic Retinopathy","authors":"Lonny Stokholm, Frederik Nørregaard Pedersen, Nis Andersen, Jens Andresen, Toke Bek, Sebastian Dinesen, Javad Hajari, Steffen Heegaard, Kurt Højlund, Caroline Schmidt Laugesen, Ryo Kawasaki, Sören Möller, Katja Christina Schielke, Yousif Subhi, Anne Suhr Thykjær, Jakob Grauslund","doi":"10.1111/aos.16707","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>To evaluate the five-year incidence of diabetic retinopathy (DR) and associated risk markers in patients with type 1 diabetes in the national Danish DR-screening programme.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Based on national data, we included all 16 999 patients with type 1 diabetes in the Danish Registry of Diabetic Retinopathy, who attended the national screening programme in the period 2013–2018. According to the worse eye at first screening, DR was classified (levels 0–4) and linked with various national health registries to retrieve information on diabetes duration, systemic comorbidity, and medication.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>At first screening, median age and duration of diabetes were 45.0 and 16.7 years, and 57.5% were males. The prevalence and five-year incidences for DR and progression to proliferative DR (PDR) were 44.2%, 8.9% and 2.0%, respectively. In multivariable Cox models, the incidence endpoints were associated with duration of diabetes (hazard ratio [HR] 1.76, 95% confidence interval [CI] 1.63–1.89, and HR 2.04, 95% CI 1.73–2.40 per 10 years), moderately low Charlson Comorbidity Index score (HR 1.27, 95% CI 1.10–1.47, and HR 2.80, 95% CI 2.23–3.51), and use of blood pressure lowering medication (HR 1.20, 95% CI 1.05–1.36, and HR 1.98, 95% CI 1.53–2.57).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In a study of all patients with type 1 diabetes from the Danish DR-screening programme, we identified duration of diabetes, systemic disease and use of anti-hypertensive treatment as consistent risk markers for incident and progressive DR.</p>\n </section>\n </div>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"102 7","pages":"805-812"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aos.16707","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aos.16707","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To evaluate the five-year incidence of diabetic retinopathy (DR) and associated risk markers in patients with type 1 diabetes in the national Danish DR-screening programme.

Methods

Based on national data, we included all 16 999 patients with type 1 diabetes in the Danish Registry of Diabetic Retinopathy, who attended the national screening programme in the period 2013–2018. According to the worse eye at first screening, DR was classified (levels 0–4) and linked with various national health registries to retrieve information on diabetes duration, systemic comorbidity, and medication.

Results

At first screening, median age and duration of diabetes were 45.0 and 16.7 years, and 57.5% were males. The prevalence and five-year incidences for DR and progression to proliferative DR (PDR) were 44.2%, 8.9% and 2.0%, respectively. In multivariable Cox models, the incidence endpoints were associated with duration of diabetes (hazard ratio [HR] 1.76, 95% confidence interval [CI] 1.63–1.89, and HR 2.04, 95% CI 1.73–2.40 per 10 years), moderately low Charlson Comorbidity Index score (HR 1.27, 95% CI 1.10–1.47, and HR 2.80, 95% CI 2.23–3.51), and use of blood pressure lowering medication (HR 1.20, 95% CI 1.05–1.36, and HR 1.98, 95% CI 1.53–2.57).

Conclusion

In a study of all patients with type 1 diabetes from the Danish DR-screening programme, we identified duration of diabetes, systemic disease and use of anti-hypertensive treatment as consistent risk markers for incident and progressive DR.

查看原文本刊更多论文

丹麦糖尿病视网膜病变登记处 16999 名 1 型糖尿病患者的糖尿病视网膜病变发生和发展情况。

目的：评估丹麦全国性糖尿病视网膜病变筛查项目中1型糖尿病患者糖尿病视网膜病变（DR）的五年发病率及相关风险指标：根据国家数据，我们将2013-2018年期间参加国家筛查计划的所有16999名1型糖尿病患者纳入丹麦糖尿病视网膜病变登记册。根据首次筛查时视力较差的眼睛，我们对糖尿病视网膜病变进行了分类（0-4 级），并将其与各种国家健康登记进行链接，以检索有关糖尿病病程、全身合并症和药物治疗的信息：首次筛查时，糖尿病患者的中位年龄和病程分别为 45.0 岁和 16.7 岁，57.5% 为男性。DR和进展为增殖性DR（PDR）的患病率和五年发病率分别为44.2%、8.9%和2.0%。在多变量 Cox 模型中，发病终点与糖尿病持续时间有关（危险比 [HR] 1.76，95% 置信区间 [CI] 1.63-1.89 和 HR 2.04，95% 置信区间 [CI] 1.73-2.40 per 10 years）、中低 Charlson Comorbidity Index 评分（HR 1.27，95% CI 1.10-1.47；HR 2.80，95% CI 2.23-3.51）、使用降压药（HR 1.20，95% CI 1.05-1.36；HR 1.98，95% CI 1.53-2.57）：在一项针对丹麦DR筛查项目中所有1型糖尿病患者的研究中，我们发现糖尿病病程、全身性疾病和使用降压药是导致DR发生和进展的一致风险标志。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Ophthalmologica 医学-眼科学

CiteScore

7.60

自引率

5.90%

发文量

433

审稿时长

6 months

期刊介绍： Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER). Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.